Gene
SLC29A1
SLC29A1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (3), Actionable biomarkers (1), Trial mentions (8), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SLC29A1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers.
SLC29A1 has 8 trial mentions across 7 years. That is too few to read as a trend, so the years are listed instead.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 0 of 8,597 | 0.00% | not measured | |
| 2023 | 0 of 8,275 | 0.00% | 4 of 11,460 | 0.03% |
| 2022 | 0 of 8,285 | 0.00% | 3 of 13,598 | 0.02% |
| 2021 | 0 of 8,692 | 0.00% | 4 of 15,045 | 0.03% |
| 2020 | 0 of 7,640 | 0.00% | 6 of 14,459 | 0.04% |
| 2019 | 0 of 7,300 | 0.00% | 10 of 12,159 | 0.08% |
| 2018 | 0 of 6,927 | 0.00% | 8 of 11,854 | 0.07% |
| 2017 | 0 of 6,558 | 0.00% | 10 of 11,595 | 0.09% |
Showing 10 of 37 years.
Assay-provider ledger (3)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Ventana Medical Systems | Unclassified | Clinical validation | 1 | August 01, 2015 |
| Clovis Oncology Inc. | Pharma or other | Clinical validation | 1 | July 01, 2014 |
| Trillium Diagnostics | Diagnostic provider | Analytical validation | 1 | Date unknown |
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SLC29A1 oncogenic mutation | GEMCITABINE | responsive | No disease recorded | Cancer Genome Interpreter |
Trial mentions (8)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT01035502 | Trial eligibility (AACT) |
| NCT01586611 | Trial eligibility (AACT) |
| NCT01411072 | Trial eligibility (AACT) |
| NCT01233375 | Trial eligibility (AACT) |
| NCT01124786 | Trial outcomes (AACT) |
Showing 5 of 8 trial mentions.
Target-disease associations (117)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Acute Leukemia | cancer or benign tumor | Literature (Europe PMC) |
| Ampulla of Vater Carcinoma | cancer or benign tumor | Literature (Europe PMC) |
| COVID-19 | infectious disease | Clinical precedence |
| COVID-19 | infectious disease | Literature (Europe PMC) |
| Calvarial doughnut lesions - bone fragility | genetic, familial or congenital disease | Mouse knockout (IMPC) |
Showing 5 of 117 associations.
Vendor sourcing (28)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AHS Cancer Control Alberta | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically documented pancreatic adenocarcinoma not previously treated with systemic therapy. * Complete macroscopic and microscopic (R0) resection ... | View trial NCT01411072 |
| AHS Cancer Control Alberta | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically documented metastatic pancreatic adenocarcinoma not previously treated with palliative systemic therapy * Metastatic disease based on the... | View trial NCT01586611 |
| AHS Cancer Control Alberta | Trial sponsor | Primary endpoint in a Phase 3 trialTrial endpoint | The difference Progression Free Survival (PFS) between Gemcitabine and FOLFOX treated patients in hENT1 high and hENT1 low pancreatic adenocarcinoma. | View trial NCT01586611 |
| AHS Cancer Control Alberta | Trial sponsor | Mentioned in trial textTrial free-text mention | hENT1 | View trial NCT01411072 |
| AHS Cancer Control Alberta | Trial sponsor | Mentioned in trial textTrial free-text mention | hENT1 | View trial NCT01586611 |
Showing 5 of 28 sourcing records.
Trial-cited literature (72)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update. | Advances in nutrition (Bethesda, Md.) | 2023 | 81 |
| Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine. | Haematologica | 2023 | 15 |
| Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait. | British journal of haematology | 2023 | 2 |
| A novel approach to overcome drug resistance in acute myeloid leukemia. | Haematologica | 2023 | 1 |
| Cancer biology and molecular genetics of A<sub>3</sub> adenosine receptor. | Oncogene | 2022 | 76 |
Showing 5 of 72 papers.
Literature-extracted relations (23)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Adenosine | Chemical | associate |
Erythrocyte type 1 equilibrative nucleoside transporter expression in sickle cell disease and sickle cell trait. | 2023 |
| Adenosine | Chemical | associate |
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. | 2020 |
| Ticagrelor | Chemical | negative_correlate |
Ticagrelor and preconditioning in patients with stable coronary artery disease (TAPER-S): a randomized pilot clinical trial. | 2020 |
| Cladribine | Chemical | associate |
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis. | 2019 |
| Dipyridamole | Chemical | negative_correlate |
Treatment of restless legs syndrome/Willis-Ekbom disease with the non-selective ENT1/ENT2 inhibitor dipyridamole: testing the adenosine hypothesis. | 2018 |
Showing 5 of 23 relation assertions.
Organizations publishing (89)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 2 | 2017 to 2018 |
| Mayo Clinic | Hospital | 2 | 2017 to 2020 |
| Memorial Sloan Kettering Cancer Center | Hospital | 2 | 2018 to 2022 |
| Newcastle University | Academic | 2 | 2016 to 2017 |
| Northwestern University | Academic | 2 | 2020 to 2023 |
Showing 5 of 89 organizations.
Where SLC29A1 appears
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- urinary system disease
114 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.